Association of COVID-19 severity with body mass index and underlying comorbid conditions-a hospital-based cross-sectional study

Raju Kannan Sampath, Aamina Hussain, Venkata Meenakshi Subramanian, Muthunarayanan Logaraj


Background: To reduce the severity of the disease among COVID-19 patients with co-morbidities is the need of the hour. Obesity may contribute to adverse outcomes in coronavirus disease 2019 (COVID-19). This study aimed to find the association between the COVID-19 biomarker values and the underlying comorbid conditions and assess the severity of the disease according to the patients' body mass index (BMI).

Methods: A single centre cross-sectional study was conducted in a tertiary hospital among 184 COVID-19 patients admitted for one month (June-July 2021).

Results: The results show a statistically significant association between the COVID-19 severity and co-morbidity status of the patients, with diabetes mellitus being the most prevalent co-morbidity among the patients, followed by diabetes with hypertension. A statistically significant association was also seen between age and co-morbidity and biomarkers and co-morbidity.

Conclusions: Obesity and other comorbid conditions like diabetes mellitus and hypertension should be given utmost importance during treatment among COVID-19 patients. Biomarker screening should be routinely done in patients with co-morbidities and obesity. Awareness among the COVID-19 patients regarding the comorbid conditions and BMI is the need of the hour.


COVID-19, Obesity, BMI

Full Text:



COVID Live Update: 245,072,311 Cases and 4,974,703 Deaths from the Coronavirus-Worldometer. Available at: Accessed on 2021 Oct, 26.

Scripting history: On 100 crore COVID-19 vaccine doses. The Hindu. 2021. Available at: Accessed on 2021 Oct, 26.

Non communicable diseases. Available at: Accessed on 2021 Oct, 26.

Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O'Rahilly S, Aveyard P et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021;9(6):350-9.

Singh R, Rathore SS, Khan H, Karale S, Bhurwal A, Tekin A et al. Association of Obesity with COVID-19 Severity and Mortality: A Systemic Review and Meta-Regression. MedRxiv. 2021;1-55.

Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P et al. Co-morbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069-76.

Mkhedr EM, Daef E, Mohamed-Hussein A, Mostafa EF, Zein M, Hassany SM et al. Impact of co-morbidities on COVID-19 outcome. medRxiv. 2020;2020.11.28.20240267.

Li M, Dong Y, Wang H, Guo W, Zhou H, Zhang Z. cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutr Metab Cardiovasc Dis. 2020;30(7):1061-7.

Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392-8.

Kang IS, Kong KA. Body mass index and severity/fatality from coronavirus disease 2019: A nationwide epidemiological study in Korea. Zhao JV, editor. PLOS ONE. 2021;16(6):e0253640.